Por: MarketWatch Business July 12, 2023
(VMW) was rising 2.3% in premarket trading after the European Commission approved ‘s (AVGO) $61 billion acquisition of the software company. rose 0.6%. (NVDA) gained 0.5% in premarket trading on a report that said Arm was discussing bringing in while the chip designer moves ahead with plans for an initial public offering later this year. One person familiar with the discussions told the Financial Times that was looking for Arm’s total... + full article
MarketWatch USA Business October 25, 2023
The companies plan to close on the transaction on Oct. 30. That is complicated by possible antitrust problems in China that may delay the closing or possibly kill the deal. The thinking on Wall Street is that the two companies could reopen the election period if the deal gets... + más
VMware Investors Should Take Stock Option in Broadcom Deal | MarketWatch
Are The EU Concerns With Broadcom’s VMware Deal Justified? | Forbes
MarketWatch USA Business September 13, 2023
VMware is a maker of software while Broadcom is a leading producer of semiconductors and its shares have benefited from enthusiasm for the AI spending boom. Those VMW holders that choose cash will receive appreciably less than the current VMware stock price. Investors who make... + más
No, Broadcom And Hock Tan Aren’t Going To Raise Prices On VMware Products | Forbes
ABC News USA Business July 12, 2023
BRUSSELS -- The European Union on Wednesday slapped a $475 million fine on U.S. biotech giant Illumina for buying out cancer-screening company Grail without the approval of the 27-nation bloc's antitrust watchdog, the latest setback for the deal.Illumina announced an $7.1... + más
Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal | CNBC
FTC orders Illumina to unwind $7B deal for cancer test developer Grail | Fox Business
ABC News USA Health July 12, 2023
ABC News USA Tech July 12, 2023
MarketWatch USA Business May 25, 2023
Illumina is holding its annual meeting at 1 p.m. Eastern time, at which the results of the proxy vote will be announced. The meeting will be held virtually, and is only open to shareholders. The stakes are high for Icahn, who needs a win. The Wall Street lion is facing an from a... + más
Illumina ordered by FTC to unwind $7b Grail deal from 2021 | The Boston Globe
CNBC USA Health March 21, 2023
In this articleCarl IcahnAdam Jeffery CNBC Biotech company pushed back Monday against Carl Icahn's proxy fight over the company's acquisition of cancer test developer Grail, saying the activist investor's board nominees do not add value. The San Diego-based DNA... + más
Carl Icahn claims Illumina directors got extra insurance to close 'disastrous' $7.1 billion Grail deal | CNBC
Icahn proposes three candidates for Illumina’s board — Here’s what could be next in the battle | CNBC
About iurex | Privacy Policy | Disclaimer |